ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence (SU-ACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02490917|
Recruitment Status : Unknown
Verified November 2017 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : July 7, 2015
Last Update Posted : November 20, 2017
The main objective is to compare the efficacy of AMS800 ™ and ACT ™ devices for the Treatment of Female Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency on "social continence" at 6 months.
Continence is defined by the average number of pads used per day. The social continence is defined by (0-1) pad per day
|Condition or disease||Intervention/treatment||Phase|
|Urinary Incontinence||Device: ACT™ device Device: AMS 800 ™ device||Not Applicable|
Prospective multicenter randomized controlled trial comparing two parallel arms: the implantation of an adjustable balloon (experimental arm) versus implantation of an artificial urinary sphincter AMS800 ™ (control arm), for the treatment of female stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD).
This research will focus on the assessment of improved continence, quality of life, and Cost-Effectiveness Analysis.
The tested device ACT ™ device is a prosthesis used to support the bladder neck and proximal urethra increasing the urethral coaptation and supporting to the bladder neck to prevent urine leakage at stress.
The medical device AMS 800 ™(control arm) is an implantable device made of silicone elastomer filled with saline/X-Ray fluid, used in the treatment of stress urinary incontinence related to ISD. It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by closing the urethra and allowing the patient to void according to the patient's will and opening of the device (sub-cutaneous pump).
An inclusion visit will take place between 3 months and 1 month before the date of the surgery to explain the purpose of the study, the benefits and risks for patients, and describe the comparative medical devices.
Patients will be randomized before surgery (at D0).
The follow-up will be conducted up to one year, with scheduled visits at M1, M3, M6 and M12.
Secondary endpoints will be assessed during scheduled visits.
The medico-economic assessment will be made during the same follow-up period. This period will take into account improvement of urinary continence and results reported from the 3rd month as well as the morbidity and mortality related to the implementation of the medical device up to 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomised Comparative Prospective Study of the Treatment of Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency : ACT™ Balloon Versus Artificial Urinary Sphincter ( AMS800™)|
|Actual Study Start Date :||September 2015|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||December 2019|
Experimental: ACT™ device
Patients randomized to receive the Adjustable Continence Therapy device ACT™
Device: ACT™ device
Implantation of the Adjustable Continence Therapy device ACT®
AMS 800 ™ device
Patients randomized to receive the artificial urinary sphincter AMS 800 ™
Device: AMS 800 ™ device
Implantation of the artificial urinary sphincter AMS 800 ™
- Social continence defined by the use of 0-1 adult protective pads per day [ Time Frame: 6 months ]
- Assessment of incontinence (number and type of protective pads used per day) [ Time Frame: 12 months ]
- impact on quality of life assessed by EQ-5D Health Questionnaire. [ Time Frame: 12 months ]
- assessment of the urinary flow using ICIQ-FLUTS questionnaire [ Time Frame: 12 months ]
- Assessment of Urinary Profile Symptoms using UPS questionnaire [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02490917
|Contact: CHARTIER-KASTLER EMMANUEL, MD, PhD||+33(0)firstname.lastname@example.org|
|Urology Department, Pitié-Salpêtrière University Hospital||Recruiting|
|Paris, France, 75013|
|Contact: CHARTIER-KASTLER EMMANUEL, MD, PhD +33(0)142177129 email@example.com|
|Principal Investigator:||CHARTIER-KASTLER EMMANUEL, MD, PhD||Urology Department, Pitié-Salpêtrière University Hospital, 75013 Paris, France|